Sonus reaches an event horizon

Sonus Pharmaceuticals Inc.'s proposed acquisition of Synt:em S.A. is one of a succession of near-term events necessary for SNUS to escape the one-product-company trap. In addition to the acquisition, in the next six months SNUS expects an agree-ment with FDA on a Phase III trial protocol for its lead product, Tocosol paclitaxel, along with a partnership for the compound. In addition, SNUS believes the Synt:em deal ultimately will allow it to raise capital on more favorable terms.

According to President and CEO Michael Martino, when SNUS morphed from an

Read the full 896 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE